ID   FGFR1_HUMAN             Reviewed;         822 AA.
AC   P11362; A8K6T9; A8K8V5; C1KBH8; P17049; Q02063; Q02065; Q14306;
AC   Q14307; Q53H63; Q59H40; Q5BJG2; Q8N685; Q9UD50; Q9UDF0; Q9UDF1;
AC   Q9UDF2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 3.
DT   10-MAY-2017, entry version 230.
DE   RecName: Full=Fibroblast growth factor receptor 1;
DE            Short=FGFR-1;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:1379697, ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753, ECO:0000269|PubMed:8622701};
DE   AltName: Full=Basic fibroblast growth factor receptor 1;
DE            Short=BFGFR;
DE            Short=bFGF-R-1;
DE   AltName: Full=Fms-like tyrosine kinase 2;
DE            Short=FLT-2;
DE   AltName: Full=N-sam;
DE   AltName: Full=Proto-oncogene c-Fgr;
DE   AltName: CD_antigen=CD331;
DE   Flags: Precursor;
GN   Name=FGFR1; Synonyms=BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 15).
RC   TISSUE=Placenta;
RX   PubMed=2162671; DOI=10.1016/0006-291X(90)90384-Y;
RA   Itoh N., Terachi T., Ohta M., Seo M.K.;
RT   "The complete amino acid sequence of the shorter form of human basic
RT   fibroblast growth factor receptor deduced from its cDNA.";
RL   Biochem. Biophys. Res. Commun. 169:680-685(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH FGF1 AND
RP   FGF2.
RC   TISSUE=Neonatal brain stem;
RX   PubMed=1697263;
RA   Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G.,
RA   Ruta M., Burgess W.H., Jaye M., Schlessinger J.;
RT   "Cloning and expression of two distinct high-affinity receptors cross-
RT   reacting with acidic and basic fibroblast growth factors.";
RL   EMBO J. 9:2685-2692(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; 15; 17 AND 18).
RX   PubMed=2167437; DOI=10.1128/MCB.10.9.4728;
RA   Johnson D.E., Lee P.L., Lu J., Williams L.T.;
RT   "Diverse forms of a receptor for acidic and basic fibroblast growth
RT   factors.";
RL   Mol. Cell. Biol. 10:4728-4736(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2159626; DOI=10.1093/nar/18.7.1906;
RA   Isacchi A., Bergonzoni L., Sarmientos P.;
RT   "Complete sequence of a human receptor for acidic and basic fibroblast
RT   growth factors.";
RL   Nucleic Acids Res. 18:1906-1906(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14), AND INTERACTION WITH FGF1 AND
RP   FGF2.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=1722683; DOI=10.3109/08977199109104816;
RA   Wennstroem S., Sandstroem C., Claesson-Welsh L.;
RT   "cDNA cloning and expression of a human FGF receptor which binds
RT   acidic and basic FGF.";
RL   Growth Factors 4:197-208(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14).
RX   PubMed=1662973; DOI=10.3109/08977199109000276;
RA   Kiefer M.C., Baird A., George-Nascimento C., Nguyen T., Mason O.B.,
RA   Boley L.J., Valenzuela P., Barr P.J.;
RT   "Molecular cloning of a human basic fibroblast growth factor receptor
RT   cDNA and expression of a biologically active extracellular domain in a
RT   baculovirus system.";
RL   Growth Factors 5:115-127(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 6; 14; 15 AND 16).
RC   TISSUE=Lung;
RX   PubMed=1650441;
RA   Eisemann A., Ahn J.A., Graziani G., Tronick S.R., Ron D.;
RT   "Alternative splicing generates at least five different isoforms of
RT   the human basic-FGF receptor.";
RL   Oncogene 6:1195-1202(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8; 9; 10;
RP   11; 12 AND 13).
RC   TISSUE=Liver;
RX   PubMed=1846977; DOI=10.1126/science.1846977;
RA   Hou J., Kan M., McKeehan K., McBride G., Adams P., McKeehan W.L.;
RT   "Fibroblast growth factor receptors from liver vary in three
RT   structural domains.";
RL   Science 251:665-668(1991).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1317750;
RA   Hattori Y., Odagiri H., Katoh O., Sakamoto H., Morita T.,
RA   Shimotohno K., Tobinai K., Sugimura T., Terada M.;
RT   "K-sam-related gene, N-sam, encodes fibroblast growth factor receptor
RT   and is expressed in T-lymphocytic tumors.";
RL   Cancer Res. 52:3367-3371(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19), AND ROLE IN DISEASE.
RX   PubMed=20139426; DOI=10.1093/humrep/deq006;
RA   Miura K., Miura S., Yoshiura K., Seminara S., Hamaguchi D.,
RA   Niikawa N., Masuzaki H.;
RT   "A case of Kallmann syndrome carrying a missense mutation in
RT   alternatively spliced exon 8A encoding the immunoglobulin-like domain
RT   IIIb of fibroblast growth factor receptor 1.";
RL   Hum. Reprod. 25:1076-1080(2010).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6; 14 AND 21).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 14 AND 20).
RC   TISSUE=Brain, and Colon;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-22; ARG-818 AND
RP   CYS-822.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 14 AND 15), AND
RP   VARIANT GLY-213.
RC   TISSUE=Pancreas, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-370 (ISOFORM 15), AND PROTEIN SEQUENCE
RP   OF 22-129 (ISOFORM 15).
RX   PubMed=7520751; DOI=10.1021/bi00200a003;
RA   Pantoliano M.W., Horlick R.A., Springer B.A., Van Dyk D.E., Tobery T.,
RA   Wetmore D.R., Lear J.D., Nahapetian A.T., Bradley J.D., Sisk W.P.;
RT   "Multivalent ligand-receptor binding interactions in the fibroblast
RT   growth factor system produce a cooperative growth factor and heparin
RT   mechanism for receptor dimerization.";
RL   Biochemistry 33:10229-10248(1994).
RN   [17]
RP   PROTEIN SEQUENCE OF 81-100 (ISOFORMS 1/2/4/5/14/16).
RX   PubMed=8074689; DOI=10.1006/bbrc.1994.2203;
RA   Rusnati M., Coltrini D., Caccia P., Dell'Era P., Zoppetti G.,
RA   Oreste P., Valsasina B., Presta M.;
RT   "Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the
RT   formation of the ternary complex with basic fibroblast growth factor
RT   and soluble FGF receptor-1.";
RL   Biochem. Biophys. Res. Commun. 203:450-458(1994).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 201-822 (ISOFORMS 1/6/10/14/15).
RA   Ruta M., Howk R., Ricca G., Drohan W., Zabelshansky M., Laureys G.,
RA   Barton D.E., Francke U., Schlessinger J., Givol D.;
RT   "A novel protein tyrosine kinase gene whose expression is modulated
RT   during endothelial cell differentiation.";
RL   Oncogene 3:9-15(1988).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-391 (ISOFORMS 17/18),
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-360 (ISOFORMS
RP   1/2/4/5/6/7/8/9/10/11/12/13/14/15), NUCLEOTIDE SEQUENCE [GENOMIC DNA /
RP   MRNA] OF 313-360 (ISOFORM 19), AND TISSUE SPECIFICITY.
RC   TISSUE=Foreskin fibroblast, and Umbilical vein;
RX   PubMed=1652059; DOI=10.1128/MCB.11.9.4627;
RA   Johnson D.E., Lu J., Chen H., Werner S., Williams L.T.;
RT   "The human fibroblast growth factor receptor genes: a common
RT   structural arrangement underlies the mechanisms for generating
RT   receptor forms that differ in their third immunoglobulin domain.";
RL   Mol. Cell. Biol. 11:4627-4634(1991).
RN   [20]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1847500; DOI=10.1128/MCB.11.3.1500;
RA   Gutkind S.J., Link D.C., Katamine S., Lacal P., Miki T., Ley T.J.,
RA   Robbins K.C.;
RT   "A novel c-fgr exon utilized in Epstein-Barr virus-infected B
RT   lymphocytes but not in normal monocytes.";
RL   Mol. Cell. Biol. 11:1500-1507(1991).
RN   [21]
RP   INTERACTION WITH PLCG1.
RX   PubMed=1656221; DOI=10.1128/MCB.11.10.5068;
RA   Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W.,
RA   Dionne C.A., Jaye M., Rubinstein M., Schlessinger J.;
RT   "A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast
RT   growth factor receptor (Flg) is a binding site for the SH2 domain of
RT   phospholipase C-gamma 1.";
RL   Mol. Cell. Biol. 11:5068-5078(1991).
RN   [22]
RP   MUTAGENESIS OF TYR-766, FUNCTION, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, AND INTERACTION WITH PLCG1.
RX   PubMed=1379697; DOI=10.1038/358678a0;
RA   Peters K.G., Marie J., Wilson E., Ives H.E., Escobedo J.,
RA   del Rosario M., Mirda D., Williams L.T.;
RT   "Point mutation of an FGF receptor abolishes phosphatidylinositol
RT   turnover and Ca2+ flux but not mitogenesis.";
RL   Nature 358:678-681(1992).
RN   [23]
RP   MUTAGENESIS OF TYR-766, AND FUNCTION IN CELL PROLIFERATION.
RX   PubMed=1379698; DOI=10.1038/358681a0;
RA   Mohammadi M., Dionne C.A., Li W., Lin N., Spivak T., Honegger A.M.,
RA   Jaye M., Schlessinger J.;
RT   "Point mutation in FGF receptor eliminates phosphatidylinositol
RT   hydrolysis without affecting mitogenesis.";
RL   Nature 358:681-684(1992).
RN   [24]
RP   MUTAGENESIS OF TYR-766, AND SUBCELLULAR LOCATION.
RX   PubMed=7516330;
RA   Sorokin A., Mohammadi M., Huang J., Schlessinger J.;
RT   "Internalization of fibroblast growth factor receptor is inhibited by
RT   a point mutation at tyrosine 766.";
RL   J. Biol. Chem. 269:17056-17061(1994).
RN   [25]
RP   PHOSPHORYLATION AT TYR-463; TYR-583; TYR-585; TYR-653; TYR-654 AND
RP   TYR-730, CATALYTIC ACTIVITY, ENZYME REGULATION, FUNCTION IN
RP   PHOSPHORYLATION OF PLCG1 AND SHC1; ACTIVATION OF MAP KINASES AND
RP   REGULATION OF CELL PROLIFERATION AND DIFFERENTIATION, AND MUTAGENESIS
RP   OF TYR-653 AND TYR-654.
RX   PubMed=8622701; DOI=10.1128/MCB.16.3.977;
RA   Mohammadi M., Dikic I., Sorokin A., Burgess W.H., Jaye M.,
RA   Schlessinger J.;
RT   "Identification of six novel autophosphorylation sites on fibroblast
RT   growth factor receptor 1 and elucidation of their importance in
RT   receptor activation and signal transduction.";
RL   Mol. Cell. Biol. 16:977-989(1996).
RN   [26]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF5; FGF6, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [27]
RP   CHROMOSOMAL TRANSLOCATION WITH ZMYM2.
RX   PubMed=9716603;
RA   Reiter A., Sohal J., Kulkarni S., Chase A., Macdonald D.H.C.,
RA   Aguiar R.C.T., Goncalves C., Hernandez J.M., Jennings B.A.,
RA   Goldman J.M., Cross N.C.P.;
RT   "Consistent fusion of ZNF198 to the fibroblast growth factor receptor-
RT   1 in the t(8;13)(p11;q12) myeloproliferative syndrome.";
RL   Blood 92:1735-1742(1998).
RN   [28]
RP   INTERACTION WITH FGF1, AND PHOSPHORYLATION.
RX   PubMed=9655399; DOI=10.1038/31741;
RA   DiGabriele A.D., Lax I., Chen D.I., Svahn C.M., Jaye M.,
RA   Schlessinger J., Hendrickson W.A.;
RT   "Structure of a heparin-linked biologically active dimer of fibroblast
RT   growth factor.";
RL   Nature 393:812-817(1998).
RN   [29]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP.
RX   PubMed=9949182;
RA   Popovici C., Zhang B., Gregoire M.-J., Jonveaux P.,
RA   Lafage-Pochitaloff M., Birnbaum D., Pebusque M.-J.;
RT   "The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative
RT   disorder fuses a novel gene, FOP, to fibroblast growth factor receptor
RT   1.";
RL   Blood 93:1381-1389(1999).
RN   [30]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568; DOI=10.1128/MCB.19.9.6217;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [31]
RP   INVOLVEMENT IN JWS, AND VARIANT JWS ARG-252.
RX   PubMed=10861678;
RX   DOI=10.1002/1096-8628(20000703)93:1<22::AID-AJMG5>3.0.CO;2-U;
RA   Roscioli T., Flanagan S., Kumar P., Masel J., Gattas M., Hyland V.J.,
RA   Glass I.A.;
RT   "Clinical findings in a patient with FGFR1 P252R mutation and
RT   comparison with the literature.";
RL   Am. J. Med. Genet. 93:22-28(2000).
RN   [32]
RP   CHROMOSOMAL TRANSLOCATION WITH CNTRL.
RX   PubMed=10688839;
RA   Guasch G., Mack G.J., Popovici C., Dastugue N., Birnbaum D.,
RA   Rattner J.B., Pebusque M.-J.;
RT   "FGFR1 is fused to the centrosome-associated protein CEP110 in the
RT   8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).";
RL   Blood 95:1788-1796(2000).
RN   [33]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2 AND GAB1 AND IN ACTIVATION OF
RP   PIK3R1.
RX   PubMed=11353842; DOI=10.1073/pnas.111114298;
RA   Ong S.H., Hadari Y.R., Gotoh N., Guy G.R., Schlessinger J., Lax I.;
RT   "Stimulation of phosphatidylinositol 3-kinase by fibroblast growth
RT   factor receptors is mediated by coordinated recruitment of multiple
RT   docking proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6074-6079(2001).
RN   [34]
RP   FUNCTION IN ACTIVATION OF SIGNALING VIA RAS AND MAP KINASES AND CELL
RP   PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2; SHB AND
RP   PTPN11/SHP2, INTERACTION WITH SHB AND FGF2, AND MUTAGENESIS OF
RP   TYR-766.
RX   PubMed=12181353; DOI=10.1091/mbc.E02-02-0103;
RA   Cross M.J., Lu L., Magnusson P., Nyqvist D., Holmqvist K., Welsh M.,
RA   Claesson-Welsh L.;
RT   "The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and
RT   regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in
RT   endothelial cells.";
RL   Mol. Biol. Cell 13:2881-2893(2002).
RN   [35]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=15034873; DOI=10.1002/gcc.20023;
RA   Grand E.K., Grand F.H., Chase A.J., Ross F.M., Corcoran M.M.,
RA   Oscier D.G., Cross N.C.P.;
RT   "Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11
RT   myeloproliferative syndrome.";
RL   Genes Chromosomes Cancer 40:78-83(2004).
RN   [36]
RP   FUNCTION IN ACTIVATION OF RPS6KA1 AND CREB1, CATALYTIC ACTIVITY,
RP   INTERACTION WITH RPS6KA1, MUTAGENESIS OF LYS-514, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15117958; DOI=10.1074/jbc.M311144200;
RA   Hu Y., Fang X., Dunham S.M., Prada C., Stachowiak E.K.,
RA   Stachowiak M.K.;
RT   "90-kDa ribosomal S6 kinase is a direct target for the nuclear
RT   fibroblast growth factor receptor 1 (FGFR1): role in FGFR1
RT   signaling.";
RL   J. Biol. Chem. 279:29325-29335(2004).
RN   [37]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-296.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [38]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=16946300; DOI=10.1182/blood-2006-06-026666;
RA   Gu T.-L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J.,
RA   Walters D.K., Wang Y., Rush J., Comb M.J., Druker B.J.,
RA   Polakiewicz R.D.;
RT   "Phosphotyrosine profiling identifies the KG-1 cell line as a model
RT   for the study of FGFR1 fusions in acute myeloid leukemia.";
RL   Blood 108:4202-4204(2006).
RN   [39]
RP   INTERACTION WITH FGF1; FGF8; FGF10; FGF19; FGF21; FGF22 AND FGF23, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [40]
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=16481405; DOI=10.1091/mbc.E05-08-0749;
RA   Dunham-Ems S.M., Pudavar H.E., Myers J.M., Maher P.A., Prasad P.N.,
RA   Stachowiak M.K.;
RT   "Factors controlling fibroblast growth factor receptor-1's cytoplasmic
RT   trafficking and its regulation as revealed by FRAP analysis.";
RL   Mol. Biol. Cell 17:2223-2235(2006).
RN   [41]
RP   PHOSPHORYLATION AT TYR-463; TYR-653; TYR-654; TYR-583 AND TYR-585, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16507368; DOI=10.1016/j.molcel.2006.01.022;
RA   Furdui C.M., Lew E.D., Schlessinger J., Anderson K.S.;
RT   "Autophosphorylation of FGFR1 kinase is mediated by a sequential and
RT   precisely ordered reaction.";
RL   Mol. Cell 21:711-717(2006).
RN   [42]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=17389761; DOI=10.1182/blood-2006-12-065615;
RA   Dong S., Kang S., Gu T., Kardar S., Fu H., Lonial S., Khoury H.J.,
RA   Khuri F., Chen J.;
RT   "14-3-3 integrates pro-survival signals mediated by the AKT and MAPK
RT   pathways in ZNF198-FGFR1 transformed hematopoietic cells.";
RL   Blood 110:360-369(2007).
RN   [43]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN REGULATION OF
RP   GLUCOSE UPTAKE IN ADIPOCYTES.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [44]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [45]
RP   BINDING TO FGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND
RP   FGF1.
RX   PubMed=18441324; DOI=10.1074/jbc.M801213200;
RA   Mori S., Wu C.Y., Yamaji S., Saegusa J., Shi B., Ma Z., Kuwabara Y.,
RA   Lam K.S., Isseroff R.R., Takada Y.K., Takada Y.;
RT   "Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1
RT   signaling.";
RL   J. Biol. Chem. 283:18066-18075(2008).
RN   [46]
RP   UBIQUITINATION, CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN
RP   ACTIVATION OF PLCG1; FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ENZYME
RP   REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18480409; DOI=10.1091/mbc.E07-12-1219;
RA   Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.;
RT   "Ubiquitination of fibroblast growth factor receptor 1 is required for
RT   its intracellular sorting but not for its endocytosis.";
RL   Mol. Biol. Cell 19:3390-3403(2008).
RN   [47]
RP   INTERACTION WITH ANOS1.
RX   PubMed=19696444; DOI=10.1074/jbc.M109.049155;
RA   Hu Y., Guimond S.E., Travers P., Cadman S., Hohenester E.,
RA   Turnbull J.E., Kim S.H., Bouloux P.M.;
RT   "Novel mechanisms of fibroblast growth factor receptor 1 regulation by
RT   extracellular matrix protein anosmin-1.";
RL   J. Biol. Chem. 284:29905-29920(2009).
RN   [48]
RP   FUNCTION IN CHROMATIN BINDING AND TRANSCRIPTION REGULATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19261810; DOI=10.1091/mbc.E08-06-0600;
RA   Dunham-Ems S.M., Lee Y.W., Stachowiak E.K., Pudavar H., Claus P.,
RA   Prasad P.N., Stachowiak M.K.;
RT   "Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a
RT   novel mechanism in transcription control.";
RL   Mol. Biol. Cell 20:2401-2412(2009).
RN   [49]
RP   FUNCTION AS PROTO-ONCOGENE, ACTIVE SITE, MUTAGENESIS OF ASP-623,
RP   CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-463; TYR-653; TYR-654;
RP   TYR-583; TYR-585 AND TYR-730, CHARACTERIZATION OF VARIANT ECCL
RP   LYS-546, IDENTIFICATION BY MASS SPECTROMETRY, AND ENZYME REGULATION.
RX   PubMed=19224897; DOI=10.1126/scisignal.2000021;
RA   Lew E.D., Furdui C.M., Anderson K.S., Schlessinger J.;
RT   "The precise sequence of FGF receptor autophosphorylation is
RT   kinetically driven and is disrupted by oncogenic mutations.";
RL   Sci. Signal. 2:RA6-RA6(2009).
RN   [50]
RP   BINDING TO FGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND
RP   FGF1.
RX   PubMed=20422052; DOI=10.1371/journal.pone.0010273;
RA   Yamaji S., Saegusa J., Ieguchi K., Fujita M., Mori S., Takada Y.K.,
RA   Takada Y.;
RT   "A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF
RT   antagonist.";
RL   PLoS ONE 5:E10273-E10273(2010).
RN   [51]
RP   INTERACTION WITH FGF23 AND KLB.
RX   PubMed=19966287; DOI=10.1073/pnas.0902006107;
RA   Goetz R., Nakada Y., Hu M.C., Kurosu H., Wang L., Nakatani T., Shi M.,
RA   Eliseenkova A.V., Razzaque M.S., Moe O.W., Kuro-o M., Mohammadi M.;
RT   "Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by
RT   inhibiting FGF23-FGFR-Klotho complex formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:407-412(2010).
RN   [52]
RP   FUNCTION IN ACTIVATION OF AKT1; PLCG1; MAPK1/ERK2, MAPK3/ERK1 AND MAP
RP   KINASE SIGNALING, FUNCTION IN REGULATION OF NEURONAL DIFFERENTIATION
RP   AND EMBRYONIC DEVELOPMENT, SUBCELLULAR LOCATION, INTERACTION WITH
RP   NEDD4; PLCG1 AND FRS2, UBIQUITINATION, AND DEGRADATION.
RX   PubMed=21765395; DOI=10.1038/emboj.2011.234;
RA   Persaud A., Alberts P., Hayes M., Guettler S., Clarke I., Sicheri F.,
RA   Dirks P., Ciruna B., Rotin D.;
RT   "Nedd4-1 binds and ubiquitylates activated FGFR1 to control its
RT   endocytosis and function.";
RL   EMBO J. 30:3259-3273(2011).
RN   [53]
RP   REVIEW ON ALTERNATIVE SPLICE FORMS; LIGANDS; SIGNALING PATHWAYS AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12141425;
RA   Groth C., Lardelli M.;
RT   "The structure and function of vertebrate fibroblast growth factor
RT   receptor 1.";
RL   Int. J. Dev. Biol. 46:393-400(2002).
RN   [54]
RP   REVIEW ON FUNCTION; ROLE IN DISEASE; SIGNALING PATHWAYS; SUBUNIT;
RP   DOMAIN STRUCTURE; LIGAND SELECTIVITY AND ENZYME REGULATION.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [55]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [56]
RP   REVIEW ON SIGNALING AND ROLE IN KALLMAN SYNDROME.
RX   PubMed=20117945; DOI=10.1016/j.tem.2010.01.004;
RA   Hu Y., Bouloux P.M.;
RT   "Novel insights in FGFR1 regulation: lessons from Kallmann syndrome.";
RL   Trends Endocrinol. Metab. 21:385-393(2010).
RN   [57]
RP   INVOLVEMENT IN ECCL, VARIANTS ECCL LYS-546 AND GLU-656, AND VARIANT
RP   MET-561.
RX   PubMed=26942290; DOI=10.1016/j.ajhg.2016.02.006;
RG   University of Washington Center for Mendelian Genomics;
RG   Care4Rare Canada Consortium;
RA   Bennett J.T., Tan T.Y., Alcantara D., Tetrault M., Timms A.E.,
RA   Jensen D., Collins S., Nowaczyk M.J., Lindhurst M.J.,
RA   Christensen K.M., Braddock S.R., Brandling-Bennett H., Hennekam R.C.,
RA   Chung B., Lehman A., Su J., Ng S., Amor D.J., Majewski J.,
RA   Biesecker L.G., Boycott K.M., Dobyns W.B., O'Driscoll M., Moog U.,
RA   McDonell L.M.;
RT   "Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous
RT   lipomatosis.";
RL   Am. J. Hum. Genet. 98:579-587(2016).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 464-762.
RX   PubMed=8752212; DOI=10.1016/S0092-8674(00)80131-2;
RA   Mohammadi M., Schlessinger J., Hubbard S.R.;
RT   "Structure of the FGF receptor tyrosine kinase domain reveals a novel
RT   autoinhibitory mechanism.";
RL   Cell 86:577-587(1996).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 464-762 IN COMPLEX WITH
RP   SU4984.
RX   PubMed=9139660; DOI=10.1126/science.276.5314.955;
RA   Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K.,
RA   Hubbard S.R., Schlessinger J.;
RT   "Structures of the tyrosine kinase domain of fibroblast growth factor
RT   receptor in complex with inhibitors.";
RL   Science 276:955-960(1997).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 141-365 IN COMPLEX WITH FGF1,
RP   FUNCTION, AND DISULFIDE BONDS.
RX   PubMed=10830168; DOI=10.1016/S0092-8674(00)80851-X;
RA   Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.;
RT   "Crystal structures of two FGF-FGFR complexes reveal the determinants
RT   of ligand-receptor specificity.";
RL   Cell 101:413-424(2000).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 143-364 IN COMPLEX WITH FGF2
RP   AND HEPARIN, AND DISULFIDE BONDS.
RX   PubMed=11030354; DOI=10.1016/S1097-2765(00)00073-3;
RA   Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V.,
RA   Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M.;
RT   "Crystal structure of a ternary FGF-FGFR-heparin complex reveals a
RT   dual role for heparin in FGFR binding and dimerization.";
RL   Mol. Cell 6:743-750(2000).
RN   [62]
RP   STRUCTURE BY NMR OF 38-124.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first Ig-like domain of human fibroblast
RT   growth factor receptor 1.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 458-774 IN COMPLEX WITH PLCG1
RP   AND ATP ANALOG, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-653; TYR-654 AND
RP   TYR-766.
RX   PubMed=19665973; DOI=10.1016/j.cell.2009.05.028;
RA   Bae J.H., Lew E.D., Yuzawa S., Tome F., Lax I., Schlessinger J.;
RT   "The selectivity of receptor tyrosine kinase signaling is controlled
RT   by a secondary SH2 domain binding site.";
RL   Cell 138:514-524(2009).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 458-765 OF MUTANT GLU-577,
RP   FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND MUTAGENESIS OF ARG-577.
RX   PubMed=20133753; DOI=10.1073/pnas.0914157107;
RA   Bae J.H., Boggon T.J., Tome F., Mandiyan V., Lax I., Schlessinger J.;
RT   "Asymmetric receptor contact is required for tyrosine
RT   autophosphorylation of fibroblast growth factor receptor in living
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2866-2871(2010).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 461-765 IN COMPLEX WITH ARQ
RP   069, AND ENZYME REGULATION.
RX   PubMed=21454610; DOI=10.1074/jbc.M110.213736;
RA   Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J.,
RA   Chen C.R., Chan T.C., France D.S., Ashwell M.A.;
RT   "A novel mode of protein kinase inhibition exploiting hydrophobic
RT   motifs of autoinhibited kinases: discovery of ATP-independent
RT   inhibitors of fibroblast growth factor receptor.";
RL   J. Biol. Chem. 286:20677-20687(2011).
RN   [66]
RP   VARIANT PS ARG-252.
RX   PubMed=7874169; DOI=10.1038/ng1194-269;
RA   Muenke M., Schell U., Hehr A., Robin N.H., Losken H.W., Schinzel A.,
RA   Pulleyn L.J., Rutland P., Reardon W., Malcolm S., Winter R.M.;
RT   "A common mutation in the fibroblast growth factor receptor 1 gene in
RT   Pfeiffer syndrome.";
RL   Nat. Genet. 8:269-274(1994).
RN   [67]
RP   VARIANT TRIGNO1 THR-300.
RX   PubMed=11173846;
RA   Kress W., Petersen B., Collmann H., Grimm T.;
RT   "An unusual FGFR1 mutation (fibroblast growth factor receptor 1
RT   mutation) in a girl with non-syndromic trigonocephaly.";
RL   Cytogenet. Cell Genet. 91:138-140(2000).
RN   [68]
RP   VARIANTS HH2 ASP-97; CYS-99; SER-167; TYR-277; MET-607; ARG-666;
RP   ARG-719 AND SER-772.
RX   PubMed=12627230; DOI=10.1038/ng1122;
RA   Dode C., Levilliers J., Dupont J.-M., De Paepe A., Le Du N.,
RA   Soussi-Yanicostas N., Coimbra R.S., Delmaghani S.,
RA   Compain-Nouaille S., Baverel F., Pecheux C., Le Tessier D., Cruaud C.,
RA   Delpech M., Speleman F., Vermeulen S., Amalfitano A., Bachelot Y.,
RA   Bouchard P., Cabrol S., Carel J.-C., Delemarre-van de Waal H.,
RA   Goulet-Salmon B., Kottler M.-L., Richard O., Sanchez-Franco F.,
RA   Saura R., Young J., Petit C., Hardelin J.-P.;
RT   "Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann
RT   syndrome.";
RL   Nat. Genet. 33:463-465(2003).
RN   [69]
RP   VARIANT HH2 SER-745.
RX   PubMed=15001591; DOI=10.1210/jc.2003-030476;
RA   Sato N., Katsumata N., Kagami M., Hasegawa T., Hori N., Kawakita S.,
RA   Minowada S., Shimotsuka A., Shishiba Y., Yokozawa M., Yasuda T.,
RA   Nagasaki K., Hasegawa D., Hasegawa Y., Tachibana K., Naiki Y.,
RA   Horikawa R., Tanaka T., Ogata T.;
RT   "Clinical assessment and mutation analysis of Kallmann syndrome 1
RT   (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in
RT   five families and 18 sporadic patients.";
RL   J. Clin. Endocrinol. Metab. 89:1079-1088(2004).
RN   [70]
RP   VARIANTS OGD ILE-330; CYS-374 AND ARG-381, AND CHARACTERIZATION OF
RP   VARIANT OGD CYS-374.
RX   PubMed=15625620; DOI=10.1086/427956;
RA   White K.E., Cabral J.M., Davis S.I., Fishburn T., Evans W.E.,
RA   Ichikawa S., Fields J., Yu X., Shaw N.J., McLellan N.J., McKeown C.,
RA   FitzPatrick D., Yu K., Ornitz D.M., Econs M.J.;
RT   "Mutations that cause osteoglophonic dysplasia define novel roles for
RT   FGFR1 in bone elongation.";
RL   Am. J. Hum. Genet. 76:361-367(2005).
RN   [71]
RP   VARIANTS HH2 ILE-102; ALA-129; MET-273 AND THR-520.
RX   PubMed=15605412; DOI=10.1002/humu.9298;
RA   Albuisson J., Pecheux C., Carel J.-C., Lacombe D., Leheup B.,
RA   Lapuzina P., Bouchard P., Legius E., Matthijs G., Wasniewska M.,
RA   Delpech M., Young J., Hardelin J.-P., Dode C.;
RT   "Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2).";
RL   Hum. Mutat. 25:98-99(2005).
RN   [72]
RP   VARIANTS HH2 ARG-687 AND SER-745.
RX   PubMed=15845591; DOI=10.1093/humrep/dei052;
RA   Sato N., Hasegawa T., Hori N., Fukami M., Yoshimura Y., Ogata T.;
RT   "Gonadotrophin therapy in Kallmann syndrome caused by heterozygous
RT   mutations of the gene for fibroblast growth factor receptor 1: report
RT   of three families: case report.";
RL   Hum. Reprod. 20:2173-2178(2005).
RN   [73]
RP   VARIANTS OGD ILE-330 AND ARG-381.
RX   PubMed=16470795; DOI=10.1002/ajmg.a.31106;
RA   Farrow E.G., Davis S.I., Mooney S.D., Beighton P., Mascarenhas L.,
RA   Gutierrez Y.R., Pitukcheewanont P., White K.E.;
RT   "Extended mutational analyses of FGFR1 in osteoglophonic dysplasia.";
RL   Am. J. Med. Genet. A 140:537-539(2006).
RN   [74]
RP   VARIANTS HH2 SER-48; PRO-245; TRP-250; VAL-343; LEU-366; SER-722 AND
RP   ILE-795.
RX   PubMed=16882753; DOI=10.1210/jc.2005-2793;
RA   Trarbach E.B., Costa E.M.F., Versiani B., de Castro M.,
RA   Baptista M.T.M., Garmes H.M., de Mendonca B.B., Latronico A.C.;
RT   "Novel fibroblast growth factor receptor 1 mutations in patients with
RT   congenital hypogonadotropic hypogonadism with and without anosmia.";
RL   J. Clin. Endocrinol. Metab. 91:4006-4012(2006).
RN   [75]
RP   VARIANTS HH2 CYS-78; ILE-102; HIS-224; ASP-237; GLN-254; MET-273;
RP   GLY-274 CYS-339; CYS-346; VAL-538; ARG-703 AND SER-703, AND VARIANT
RP   VAL-769.
RX   PubMed=16764984; DOI=10.1016/j.mce.2006.04.021;
RA   Pitteloud N., Meysing A., Quinton R., Acierno J.S. Jr., Dwyer A.A.,
RA   Plummer L., Fliers E., Boepple P., Hayes F., Seminara S., Hughes V.A.,
RA   Ma J., Bouloux P., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause Kallmann
RT   syndrome with a wide spectrum of reproductive phenotypes.";
RL   Mol. Cell. Endocrinol. 254:60-69(2006).
RN   [76]
RP   VARIANTS HH2 SER-178; GLY-622 AND GLN-622.
RX   PubMed=16757108; DOI=10.1016/j.mce.2006.04.006;
RA   Zenaty D., Bretones P., Lambe C., Guemas I., David M., Leger J.,
RA   de Roux N.;
RT   "Paediatric phenotype of Kallmann syndrome due to mutations of
RT   fibroblast growth factor receptor 1 (FGFR1).";
RL   Mol. Cell. Endocrinol. 254:78-83(2006).
RN   [77]
RP   VARIANTS HH2 SER-237; HIS-722 AND LYS-724, AND CHARACTERIZATION OF
RP   VARIANTS HH2 SER-237; HIS-722 AND LYS-724.
RX   PubMed=16606836; DOI=10.1073/pnas.0600962103;
RA   Pitteloud N., Acierno J.S. Jr., Meysing A., Eliseenkova A.V., Ma J.,
RA   Ibrahimi O.A., Metzger D.L., Hayes F.J., Dwyer A.A., Hughes V.A.,
RA   Yialamas M., Hall J.E., Grant E., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause both Kallmann
RT   syndrome and normosmic idiopathic hypogonadotropic hypogonadism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6281-6286(2006).
RN   [78]
RP   VARIANTS HH2 PHE-101; TRP-250; ASP-270; ARG-283; CYS-332; ARG-621;
RP   PHE-685; PHE-693 AND SER-772, AND VARIANTS LYS-77 AND CYS-822.
RX   PubMed=17154279; DOI=10.1002/humu.9470;
RA   Dode C., Fouveaut C., Mortier G., Janssens S., Bertherat J.,
RA   Mahoudeau J., Kottler M.-L., Chabrolle C., Gancel A., Francois I.,
RA   Devriendt K., Wolczynski S., Pugeat M., Pineiro-Garcia A., Murat A.,
RA   Bouchard P., Young J., Delpech M., Hardelin J.-P.;
RT   "Novel FGFR1 sequence variants in Kallmann syndrome, and genetic
RT   evidence that the FGFR1c isoform is required in olfactory bulb and
RT   palate morphogenesis.";
RL   Hum. Mutat. 28:97-98(2007).
RN   [79]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-125; THR-252 AND LEU-664.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [80]
RP   VARIANTS HH2 CYS-99; SER-117; ASP-228; THR-239; GLN-250; LEU-470;
RP   ASN-618 AND PRO-671, AND CHARACTERIZATION OF VARIANTS HH2 CYS-99;
RP   SER-117; ASP-228; THR-239; GLN-250; LEU-470; ASN-618 AND PRO-671.
RX   PubMed=19820032; DOI=10.1210/jc.2009-0179;
RA   Raivio T., Sidis Y., Plummer L., Chen H., Ma J., Mukherjee A.,
RA   Jacobson-Dickman E., Quinton R., Van Vliet G., Lavoie H., Hughes V.A.,
RA   Dwyer A., Hayes F.J., Xu S., Sparks S., Kaiser U.B., Mohammadi M.,
RA   Pitteloud N.;
RT   "Impaired fibroblast growth factor receptor 1 signaling as a cause of
RT   normosmic idiopathic hypogonadotropic hypogonadism.";
RL   J. Clin. Endocrinol. Metab. 94:4380-4390(2009).
RN   [81]
RP   VARIANT HH2 GLN-250.
RX   PubMed=21700882; DOI=10.1073/pnas.1102284108;
RA   Tornberg J., Sykiotis G.P., Keefe K., Plummer L., Hoang X., Hall J.E.,
RA   Quinton R., Seminara S.B., Hughes V., Van Vliet G., Van Uum S.,
RA   Crowley W.F., Habuchi H., Kimata K., Pitteloud N., Bulow H.E.;
RT   "Heparan sulfate 6-O-sulfotransferase 1, a gene involved in
RT   extracellular sugar modifications, is mutated in patients with
RT   idiopathic hypogonadotrophic hypogonadism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11524-11529(2011).
RN   [82]
RP   VARIANT HH2 ARG-687.
RX   PubMed=22927827; DOI=10.1371/journal.pgen.1002896;
RA   Hanchate N.K., Giacobini P., Lhuillier P., Parkash J., Espy C.,
RA   Fouveaut C., Leroy C., Baron S., Campagne C., Vanacker C., Collier F.,
RA   Cruaud C., Meyer V., Garcia-Pinero A., Dewailly D., Cortet-Rudelli C.,
RA   Gersak K., Metz C., Chabrier G., Pugeat M., Young J., Hardelin J.P.,
RA   Prevot V., Dode C.;
RT   "SEMA3A, a gene involved in axonal pathfinding, is mutated in patients
RT   with Kallmann syndrome.";
RL   PLoS Genet. 8:E1002896-E1002896(2012).
RN   [83]
RP   VARIANTS HH2 SER-117; ASP-228; THR-239; GLN-250; SER-342; ARG-348;
RP   LEU-470; THR-483; ASN-618; LYS-670; GLY-692; HIS-722; LYS-724 AND
RP   TYR-768.
RX   PubMed=23643382; DOI=10.1016/j.ajhg.2013.04.008;
RA   Miraoui H., Dwyer A.A., Sykiotis G.P., Plummer L., Chung W., Feng B.,
RA   Beenken A., Clarke J., Pers T.H., Dworzynski P., Keefe K.,
RA   Niedziela M., Raivio T., Crowley W.F. Jr., Seminara S.B., Quinton R.,
RA   Hughes V.A., Kumanov P., Young J., Yialamas M.A., Hall J.E.,
RA   Van Vliet G., Chanoine J.P., Rubenstein J., Mohammadi M., Tsai P.S.,
RA   Sidis Y., Lage K., Pitteloud N.;
RT   "Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in
RT   individuals with congenital hypogonadotropic hypogonadism.";
RL   Am. J. Hum. Genet. 92:725-743(2013).
RN   [84]
RP   INVOLVEMENT IN HRTFDS, AND VARIANTS HRTFDS SER-165; SER-191; ARG-490;
RP   TYR-623; LYS-628 AND TYR-725.
RX   PubMed=23812909; DOI=10.1136/jmedgenet-2013-101603;
RA   Simonis N., Migeotte I., Lambert N., Perazzolo C., de Silva D.C.,
RA   Dimitrov B., Heinrichs C., Janssens S., Kerr B., Mortier G.,
RA   Van Vliet G., Lepage P., Casimir G., Abramowicz M., Smits G.,
RA   Vilain C.;
RT   "FGFR1 mutations cause Hartsfield syndrome, the unique association of
RT   holoprosencephaly and ectrodactyly.";
RL   J. Med. Genet. 50:585-592(2013).
RN   [85]
RP   VARIANT HRTFDS THR-627.
RX   PubMed=24888332; DOI=10.1002/ajmg.a.36621;
RA   Dhamija R., Kirmani S., Wang X., Ferber M.J., Wieben E.D.,
RA   Lazaridis K.N., Babovic-Vuksanovic D.;
RT   "Novel de novo heterozygous FGFR1 mutation in two siblings with
RT   Hartsfield syndrome: A case of gonadal mosaicism.";
RL   Am. J. Med. Genet. A 164:2356-2359(2014).
RN   [86]
RP   VARIANTS HH2 ARG-70; ILE-116; ALA-174; GLN-250 AND ARG-348.
RX   PubMed=25077900; DOI=10.1210/jc.2014-2110;
RA   Marcos S., Sarfati J., Leroy C., Fouveaut C., Parent P., Metz C.,
RA   Wolczynski S., Gerard M., Bieth E., Kurtz F., Verier-Mine O.,
RA   Perrin L., Archambeaud F., Cabrol S., Rodien P., Hove H., Prescott T.,
RA   Lacombe D., Christin-Maitre S., Touraine P., Hieronimus S.,
RA   Dewailly D., Young J., Pugeat M., Hardelin J.P., Dode C.;
RT   "The prevalence of CHD7 missense versus truncating mutations is higher
RT   in patients with Kallmann syndrome than in typical CHARGE patients.";
RL   J. Clin. Endocrinol. Metab. 99:E2138-2143(2014).
RN   [87]
RP   VARIANTS HH2 CYS-4; CYS-96 AND VAL-719, AND VARIANT HH2 THR-353
RP   (ISOFORM 19).
RX   PubMed=26277103; DOI=10.1016/j.fertnstert.2015.07.1142;
RA   Goncalves C., Bastos M., Pignatelli D., Borges T., Araguees J.M.,
RA   Fonseca F., Pereira B.D., Socorro S., Lemos M.C.;
RT   "Novel FGFR1 mutations in Kallmann syndrome and normosmic idiopathic
RT   hypogonadotropic hypogonadism: evidence for the involvement of an
RT   alternatively spliced isoform.";
RL   Fertil. Steril. 0:0-0(2015).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of embryonic development, cell proliferation,
CC       differentiation and migration. Required for normal mesoderm
CC       patterning and correct axial organization during embryonic
CC       development, normal skeletogenesis and normal development of the
CC       gonadotropin-releasing hormone (GnRH) neuronal system.
CC       Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to
CC       the activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2.
CC       In the nucleus, enhances RPS6KA1 and CREB1 activity and
CC       contributes to the regulation of transcription. FGFR1 signaling is
CC       down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination,
CC       internalization and degradation. {ECO:0000250|UniProtKB:P16092,
CC       ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11353842,
CC       ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:1379698, ECO:0000269|PubMed:15117958,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19261810,
CC       ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753,
CC       ECO:0000269|PubMed:20139426, ECO:0000269|PubMed:21765395,
CC       ECO:0000269|PubMed:8622701, ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973,
CC       ECO:0000269|PubMed:20133753, ECO:0000269|PubMed:8622701}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by sequential autophosphorylation on tyrosine residues.
CC       Inhibited by ARQ 069; this compound maintains the kinase in an
CC       inactive conformation and inhibits autophosphorylation. Inhibited
CC       by PD173074. {ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:21454610,
CC       ECO:0000269|PubMed:8622701}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts
CC       predominantly with FGF1 and FGF2, but can also interact with FGF3,
CC       FGF4, FGF5, FGF6, FGF8, FGF10, FGF19, FGF21, FGF22 and FGF23 (in
CC       vitro) (PubMed:1697263, PubMed:1722683, PubMed:8663044,
CC       PubMed:9655399, PubMed:12181353, PubMed:16597617,
CC       PubMed:17623664). Ligand specificity is determined by tissue-
CC       specific expression of isoforms, and differences in the third Ig-
CC       like domain are crucial for ligand specificity. Affinity for
CC       fibroblast growth factors (FGFs) is increased by heparan sulfate
CC       glycosaminoglycans that function as coreceptors. Likewise, KLB
CC       increases the affinity for FGF19, FGF21 and FGF23
CC       (PubMed:19966287). Interacts (phosphorylated on Tyr-766) with
CC       PLCG1 (via SH2 domains) (PubMed:1656221, PubMed:1379697,
CC       PubMed:21765395). Interacts with FRS2 (PubMed:21765395). Interacts
CC       with RPS6KA1 (PubMed:15117958). Interacts (via C-terminus) with
CC       NEDD4 (via WW3 domain) (PubMed:21765395). Interacts with KL (By
CC       similarity). Interacts with SHB (via SH2 domain)
CC       (PubMed:12181353). Interacts with GRB10 (PubMed:10454568).
CC       Interacts with ANOS1; this interaction does not interfere with
CC       FGF2-binding to FGFR1, but prevents binding of heparin-bound FGF2
CC       (PubMed:19696444). Interacts with SOX2 and SOX3. Interacts with
CC       FLRT1, FLRT2 and FLRT3 (By similarity). Found in a ternary complex
CC       with FGF1 and ITGAV:ITGB3 (PubMed:20422052, PubMed:18441324).
CC       {ECO:0000250|UniProtKB:P16092, ECO:0000269|PubMed:10454568,
CC       ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:1656221,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:1697263,
CC       ECO:0000269|PubMed:1722683, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:18441324, ECO:0000269|PubMed:19696444,
CC       ECO:0000269|PubMed:19966287, ECO:0000269|PubMed:20422052,
CC       ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:8663044,
CC       ECO:0000269|PubMed:9655399}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-1028277, EBI-1028277;
CC       P23352:ANOS1; NbExp=7; IntAct=EBI-1028277, EBI-5272188;
CC       P12830:CDH1; NbExp=3; IntAct=EBI-1028277, EBI-727477;
CC       P46108:CRK; NbExp=2; IntAct=EBI-1028277, EBI-886;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-1028277, EBI-491549;
CC       P05230:FGF1; NbExp=3; IntAct=EBI-1028277, EBI-698068;
CC       P09038:FGF2; NbExp=5; IntAct=EBI-1028277, EBI-977447;
CC       O88900:Grb14 (xeno); NbExp=3; IntAct=EBI-1028277, EBI-7639197;
CC       P08908:HTR1A; NbExp=11; IntAct=EBI-1028277, EBI-6570214;
CC       P46934:NEDD4; NbExp=26; IntAct=EBI-1028277, EBI-726944;
CC       Q8IVI9:NOSTRIN; NbExp=5; IntAct=EBI-1028277, EBI-1391643;
CC       P27986:PIK3R1; NbExp=5; IntAct=EBI-1028277, EBI-79464;
CC       P19174:PLCG1; NbExp=5; IntAct=EBI-1028277, EBI-79387;
CC       P10686:Plcg1 (xeno); NbExp=4; IntAct=EBI-1028277, EBI-520788;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Nucleus. Cytoplasm, cytosol. Cytoplasmic vesicle.
CC       Note=After ligand binding, both receptor and ligand are rapidly
CC       internalized. Can translocate to the nucleus after
CC       internalization, or by translocation from the endoplasmic
CC       reticulum or Golgi apparatus to the cytosol, and from there to the
CC       nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=21;
CC       Name=1; Synonyms=Alpha A1, IV;
CC         IsoId=P11362-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha A2;
CC         IsoId=P11362-8; Sequence=VSP_009842, VSP_009843;
CC       Name=3; Synonyms=Alpha A3;
CC         IsoId=P11362-17; Sequence=VSP_009836, VSP_009837;
CC       Name=4; Synonyms=Alpha B1;
CC         IsoId=P11362-2; Sequence=VSP_002960;
CC       Name=5; Synonyms=Alpha B2;
CC         IsoId=P11362-9; Sequence=VSP_002960, VSP_009842, VSP_009843;
CC       Name=6; Synonyms=Beta A1, II, H2;
CC         IsoId=P11362-3; Sequence=VSP_002958;
CC       Name=7; Synonyms=Beta A2;
CC         IsoId=P11362-10; Sequence=VSP_002958, VSP_009842, VSP_009843;
CC       Name=8; Synonyms=Beta B1;
CC         IsoId=P11362-4; Sequence=VSP_002958, VSP_002960;
CC       Name=9; Synonyms=Beta B2;
CC         IsoId=P11362-11; Sequence=VSP_002958, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=10; Synonyms=Gamma A1;
CC         IsoId=P11362-5; Sequence=VSP_002957;
CC       Name=11; Synonyms=Gamma A2;
CC         IsoId=P11362-12; Sequence=VSP_002957, VSP_009842, VSP_009843;
CC       Name=12; Synonyms=Gamma B1;
CC         IsoId=P11362-6; Sequence=VSP_002957, VSP_002960;
CC       Name=13; Synonyms=Gamma B2;
CC         IsoId=P11362-13; Sequence=VSP_002957, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=14; Synonyms=A, III;
CC         IsoId=P11362-7; Sequence=VSP_002959;
CC       Name=15; Synonyms=I, H3;
CC         IsoId=P11362-14; Sequence=VSP_002958, VSP_002959;
CC       Name=16; Synonyms=V;
CC         IsoId=P11362-15; Sequence=VSP_009838, VSP_009839;
CC       Name=17; Synonyms=H4;
CC         IsoId=P11362-16; Sequence=VSP_002958, VSP_009840, VSP_009841;
CC       Name=18; Synonyms=H5;
CC         IsoId=P11362-18; Sequence=VSP_002958, VSP_002959, VSP_009840,
CC                                   VSP_009841;
CC       Name=19;
CC         IsoId=P11362-19; Sequence=VSP_038470, VSP_002959, VSP_038471;
CC         Note=Variant in position: 353:A->T (in HH2, unknown pathological
CC         significance). {ECO:0000269|PubMed:26277103};
CC       Name=20;
CC         IsoId=P11362-20; Sequence=VSP_041916, VSP_041918;
CC       Name=21;
CC         IsoId=P11362-21; Sequence=VSP_041917, VSP_002959;
CC   -!- TISSUE SPECIFICITY: Detected in astrocytoma, neuroblastoma and
CC       adrenal cortex cell lines. Some isoforms are detected in foreskin
CC       fibroblast cell lines, however isoform 17, isoform 18 and isoform
CC       19 are not detected in these cells. {ECO:0000269|PubMed:1652059}.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. Isoforms lacking the first Ig-like domain have
CC       higher affinity for fibroblast growth factors (FGF) and heparan
CC       sulfate proteoglycans than isoforms with all three Ig-like
CC       domains.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer and proceeds in a highly ordered manner.
CC       Initial autophosphorylation at Tyr-653 increases the kinase
CC       activity by a factor of 50 to 100. After this, Tyr-583 becomes
CC       phosphorylated, followed by phosphorylation of Tyr-463, Tyr-766,
CC       Tyr-583 and Tyr-585. In a third stage, Tyr-654 is
CC       autophosphorylated, resulting in a further tenfold increase of
CC       kinase activity. Phosphotyrosine residues provide docking sites
CC       for interacting proteins and so are crucial for FGFR1 function and
CC       its regulation. {ECO:0000269|PubMed:16507368,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973,
CC       ECO:0000269|PubMed:8622701}.
CC   -!- PTM: Ubiquitinated. FGFR1 is rapidly ubiquitinated by NEDD4 after
CC       autophosphorylation, leading to internalization and lysosomal
CC       degradation. CBL is recruited to activated FGFR1 via FRS2 and
CC       GRB2, and mediates ubiquitination and subsequent degradation of
CC       FGFR1. {ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:21765395}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus. {ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:16481405, ECO:0000269|PubMed:17311277}.
CC   -!- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome
CC       characterized by the association of craniosynostosis, broad and
CC       deviated thumbs and big toes, and partial syndactyly of the
CC       fingers and toes. Three subtypes are known: mild autosomal
CC       dominant form (type 1); cloverleaf skull, elbow ankylosis, early
CC       death, sporadic (type 2); craniosynostosis, early demise, sporadic
CC       (type 3). {ECO:0000269|PubMed:7874169}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypogonadotropic hypogonadism 2 with or without anosmia
CC       (HH2) [MIM:147950]: A disorder characterized by absent or
CC       incomplete sexual maturation by the age of 18 years, in
CC       conjunction with low levels of circulating gonadotropins and
CC       testosterone and no other abnormalities of the hypothalamic-
CC       pituitary axis. In some cases, it is associated with non-
CC       reproductive phenotypes, such as anosmia, cleft palate, and
CC       sensorineural hearing loss. Anosmia or hyposmia is related to the
CC       absence or hypoplasia of the olfactory bulbs and tracts.
CC       Hypogonadism is due to deficiency in gonadotropin-releasing
CC       hormone and probably results from a failure of embryonic migration
CC       of gonadotropin-releasing hormone-synthesizing neurons. In the
CC       presence of anosmia, idiopathic hypogonadotropic hypogonadism is
CC       referred to as Kallmann syndrome, whereas in the presence of a
CC       normal sense of smell, it has been termed normosmic idiopathic
CC       hypogonadotropic hypogonadism (nIHH).
CC       {ECO:0000269|PubMed:12627230, ECO:0000269|PubMed:15001591,
CC       ECO:0000269|PubMed:15605412, ECO:0000269|PubMed:15845591,
CC       ECO:0000269|PubMed:16606836, ECO:0000269|PubMed:16757108,
CC       ECO:0000269|PubMed:16764984, ECO:0000269|PubMed:16882753,
CC       ECO:0000269|PubMed:17154279, ECO:0000269|PubMed:19820032,
CC       ECO:0000269|PubMed:21700882, ECO:0000269|PubMed:22927827,
CC       ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900,
CC       ECO:0000269|PubMed:26277103}. Note=The disease is caused by
CC       mutations affecting distinct genetic loci, including the gene
CC       represented in this entry. Some patients carrying mutations in
CC       FGFR1 also have a mutation other HH-associated genes including
CC       DUSP6, FGF8, FGF17, FLRT3, GNRH1, GNRHR, HS6ST1, IL17RD, ANOS1,
CC       KISS1R, NSMF, PROKR2, SPRY4 and TACR3 (PubMed:23643382).
CC       {ECO:0000269|PubMed:23643382}.
CC   -!- DISEASE: Osteoglophonic dysplasia (OGD) [MIM:166250]:
CC       Characterized by craniosynostosis, prominent supraorbital ridge,
CC       and depressed nasal bridge, as well as by rhizomelic dwarfism and
CC       nonossifying bone lesions. Inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:15625620, ECO:0000269|PubMed:16470795}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Hartsfield syndrome (HRTFDS) [MIM:615465]: A syndrome
CC       characterized by the triad of holoprosencephaly, ectrodactyly, and
CC       cleft/lip palate. Profound mental retardation is also present.
CC       Multiple other congenital anomalies usually occur.
CC       {ECO:0000269|PubMed:23812909, ECO:0000269|PubMed:24888332}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Trigonocephaly 1 (TRIGNO1) [MIM:190440]: A keel-shaped
CC       deformation of the forehead, caused by premature fusion of the
CC       metopic sutures. It results in a triangular shape of the head.
CC       {ECO:0000269|PubMed:11173846}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell leukemia lymphoma syndrome (SCLL).
CC       Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents
CC       as lymphoblastic lymphoma in association with a myeloproliferative
CC       disorder, often accompanied by pronounced peripheral eosinophilia
CC       and/or prominent eosinophilic infiltrates in the affected bone
CC       marrow. {ECO:0000269|PubMed:9716603}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell myeloproliferative disorder (MPD).
CC       Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion
CC       ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by
CC       myeloid hyperplasia, eosinophilia and T-cell or B-cell
CC       lymphoblastic lymphoma. In general it progresses to acute myeloid
CC       leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or
CC       FGFR1-FGFR1OP may exhibit constitutive kinase activity and be
CC       responsible for the transforming activity.
CC       {ECO:0000269|PubMed:10688839, ECO:0000269|PubMed:15034873,
CC       ECO:0000269|PubMed:16946300, ECO:0000269|PubMed:17389761,
CC       ECO:0000269|PubMed:9949182}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell myeloproliferative disorder (MPD).
CC       Translocation t(8;9)(p12;q33) with CNTRL. MPD is characterized by
CC       myeloid hyperplasia, eosinophilia and T-cell or B-cell
CC       lymphoblastic lymphoma. In general it progresses to acute myeloid
CC       leukemia. The fusion protein CNTRL-FGFR1 is found in the
CC       cytoplasm, exhibits constitutive kinase activity and may be
CC       responsible for the transforming activity.
CC   -!- DISEASE: Encephalocraniocutaneous lipomatosis (ECCL) [MIM:613001]:
CC       A sporadically occurring, neurocutaneous disorder characterized by
CC       ocular anomalies, skin lesions, and central nervous system
CC       anomalies. Clinical features include a well-demarcated hairless
CC       fatty nevus on the scalp, benign ocular tumors, intracranial and
CC       intraspinal lipomas, and congenital abnormalities of the meninges.
CC       Seizures, spasticity, and intellectual disability can be present.
CC       {ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:26942290}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal
CC       dominant craniosynostosis syndrome characterized by craniofacial
CC       abnormalities and abnormality of the feet: broad great toes with
CC       medial deviation and tarsal-metatarsal coalescence.
CC       {ECO:0000269|PubMed:10861678}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92156.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR1ID113.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M37722; AAA75007.1; -; mRNA.
DR   EMBL; X52833; CAA37015.1; -; mRNA.
DR   EMBL; M34185; AAA35836.1; -; mRNA.
DR   EMBL; M34186; AAA35837.1; -; mRNA.
DR   EMBL; M34187; AAA35838.1; -; mRNA.
DR   EMBL; M34188; AAA35839.1; -; mRNA.
DR   EMBL; X51803; CAA36101.1; -; mRNA.
DR   EMBL; M34641; AAA35835.1; -; mRNA.
DR   EMBL; M60485; AAA35840.1; -; mRNA.
DR   EMBL; X57118; CAA40400.1; -; mRNA.
DR   EMBL; X57119; CAA40401.1; -; mRNA.
DR   EMBL; X57120; CAA40402.1; -; mRNA.
DR   EMBL; X57121; CAA40403.1; -; mRNA.
DR   EMBL; X57122; CAA40404.1; -; mRNA.
DR   EMBL; M63887; AAA35958.1; -; mRNA.
DR   EMBL; M63888; AAA35959.1; -; mRNA.
DR   EMBL; M63889; AAA35960.1; -; mRNA.
DR   EMBL; X66945; CAA47375.1; -; mRNA.
DR   EMBL; FJ809917; ACO38646.1; -; mRNA.
DR   EMBL; AK291754; BAF84443.1; -; mRNA.
DR   EMBL; AK292470; BAF85159.1; -; mRNA.
DR   EMBL; AK309947; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB208919; BAD92156.1; ALT_INIT; mRNA.
DR   EMBL; AK222718; BAD96438.1; -; mRNA.
DR   EMBL; AY585209; AAS79322.1; -; Genomic_DNA.
DR   EMBL; AC087623; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015035; AAH15035.1; -; mRNA.
DR   EMBL; BC018128; AAH18128.1; -; mRNA.
DR   EMBL; BC091494; AAH91494.1; -; mRNA.
DR   EMBL; Y00665; CAA68679.1; -; mRNA.
DR   CCDS; CCDS43730.1; -. [P11362-3]
DR   CCDS; CCDS43731.1; -. [P11362-14]
DR   CCDS; CCDS43732.1; -. [P11362-7]
DR   CCDS; CCDS55221.1; -. [P11362-20]
DR   CCDS; CCDS55222.1; -. [P11362-2]
DR   CCDS; CCDS55223.1; -. [P11362-21]
DR   CCDS; CCDS6107.2; -. [P11362-1]
DR   PIR; A41266; A41266.
DR   PIR; C36464; C36464.
DR   PIR; C40862; C40862.
DR   PIR; S11692; TVHUFG.
DR   PIR; S19167; A40862.
DR   RefSeq; NP_001167534.1; NM_001174063.1. [P11362-2]
DR   RefSeq; NP_001167535.1; NM_001174064.1. [P11362-20]
DR   RefSeq; NP_001167536.1; NM_001174065.1. [P11362-7]
DR   RefSeq; NP_001167537.1; NM_001174066.1. [P11362-3]
DR   RefSeq; NP_001167538.1; NM_001174067.1. [P11362-21]
DR   RefSeq; NP_056934.2; NM_015850.3. [P11362-7]
DR   RefSeq; NP_075593.1; NM_023105.2. [P11362-3]
DR   RefSeq; NP_075594.1; NM_023106.2. [P11362-14]
DR   RefSeq; NP_075598.2; NM_023110.2. [P11362-1]
DR   UniGene; Hs.264887; -.
DR   PDB; 1AGW; X-ray; 2.40 A; A/B=456-765.
DR   PDB; 1CVS; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1EVT; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1FGI; X-ray; 2.50 A; A/B=456-765.
DR   PDB; 1FGK; X-ray; 2.00 A; A/B=456-765.
DR   PDB; 1FQ9; X-ray; 3.00 A; C/D=141-365.
DR   PDB; 1XR0; NMR; -; A=409-430.
DR   PDB; 2CR3; NMR; -; A=38-123.
DR   PDB; 2FGI; X-ray; 2.50 A; A/B=456-765.
DR   PDB; 3C4F; X-ray; 2.07 A; A/B=464-765.
DR   PDB; 3DPK; X-ray; 1.95 A; A=577-615.
DR   PDB; 3GQI; X-ray; 2.50 A; A=458-774.
DR   PDB; 3GQL; X-ray; 2.80 A; A/B/C=458-774.
DR   PDB; 3JS2; X-ray; 2.20 A; A/B=458-765.
DR   PDB; 3KRJ; X-ray; 2.10 A; A=577-597.
DR   PDB; 3KRL; X-ray; 2.40 A; A=577-597.
DR   PDB; 3KXX; X-ray; 3.20 A; A/B/C/D=458-765.
DR   PDB; 3KY2; X-ray; 2.70 A; A/B=458-765.
DR   PDB; 3OJV; X-ray; 2.60 A; C/D=142-365.
DR   PDB; 3RHX; X-ray; 2.01 A; A/B=461-765.
DR   PDB; 3TT0; X-ray; 2.80 A; A/B=456-765.
DR   PDB; 4F63; X-ray; 2.55 A; A/B=458-765.
DR   PDB; 4F64; X-ray; 2.05 A; A/B=458-765.
DR   PDB; 4F65; X-ray; 2.26 A; A/B=458-765.
DR   PDB; 4NK9; X-ray; 2.57 A; A/B=458-765.
DR   PDB; 4NKA; X-ray; 2.19 A; A/B=458-765.
DR   PDB; 4NKS; X-ray; 2.50 A; A/B=458-765.
DR   PDB; 4RWI; X-ray; 2.29 A; A/B=458-765.
DR   PDB; 4RWJ; X-ray; 2.49 A; A/B=458-765.
DR   PDB; 4RWK; X-ray; 2.98 A; A/B=458-765.
DR   PDB; 4RWL; X-ray; 2.19 A; A/B=458-765.
DR   PDB; 4UWB; X-ray; 2.31 A; A/B=458-765.
DR   PDB; 4UWC; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 4UWY; X-ray; 2.31 A; A/B=458-765.
DR   PDB; 4V01; X-ray; 2.33 A; A/B=458-765.
DR   PDB; 4V04; X-ray; 2.12 A; A/B=458-765.
DR   PDB; 4V05; X-ray; 2.57 A; A/B=458-765.
DR   PDB; 4WUN; X-ray; 1.65 A; A/B=459-765.
DR   PDB; 4ZSA; X-ray; 2.00 A; A/B=458-765.
DR   PDB; 5A46; X-ray; 2.63 A; A/B=437-822.
DR   PDB; 5A4C; X-ray; 2.09 A; A/B=461-765.
DR   PDB; 5AM6; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 5AM7; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 5B7V; X-ray; 2.15 A; A/B=456-765.
DR   PDB; 5EW8; X-ray; 1.63 A; A/B=458-765.
DR   PDB; 5FLF; X-ray; 2.58 A; A/B/C/D/E=458-765.
DR   PDB; 5UQ0; X-ray; 2.30 A; A/B=459-765.
DR   PDBsum; 1AGW; -.
DR   PDBsum; 1CVS; -.
DR   PDBsum; 1EVT; -.
DR   PDBsum; 1FGI; -.
DR   PDBsum; 1FGK; -.
DR   PDBsum; 1FQ9; -.
DR   PDBsum; 1XR0; -.
DR   PDBsum; 2CR3; -.
DR   PDBsum; 2FGI; -.
DR   PDBsum; 3C4F; -.
DR   PDBsum; 3DPK; -.
DR   PDBsum; 3GQI; -.
DR   PDBsum; 3GQL; -.
DR   PDBsum; 3JS2; -.
DR   PDBsum; 3KRJ; -.
DR   PDBsum; 3KRL; -.
DR   PDBsum; 3KXX; -.
DR   PDBsum; 3KY2; -.
DR   PDBsum; 3OJV; -.
DR   PDBsum; 3RHX; -.
DR   PDBsum; 3TT0; -.
DR   PDBsum; 4F63; -.
DR   PDBsum; 4F64; -.
DR   PDBsum; 4F65; -.
DR   PDBsum; 4NK9; -.
DR   PDBsum; 4NKA; -.
DR   PDBsum; 4NKS; -.
DR   PDBsum; 4RWI; -.
DR   PDBsum; 4RWJ; -.
DR   PDBsum; 4RWK; -.
DR   PDBsum; 4RWL; -.
DR   PDBsum; 4UWB; -.
DR   PDBsum; 4UWC; -.
DR   PDBsum; 4UWY; -.
DR   PDBsum; 4V01; -.
DR   PDBsum; 4V04; -.
DR   PDBsum; 4V05; -.
DR   PDBsum; 4WUN; -.
DR   PDBsum; 4ZSA; -.
DR   PDBsum; 5A46; -.
DR   PDBsum; 5A4C; -.
DR   PDBsum; 5AM6; -.
DR   PDBsum; 5AM7; -.
DR   PDBsum; 5B7V; -.
DR   PDBsum; 5EW8; -.
DR   PDBsum; 5FLF; -.
DR   PDBsum; 5UQ0; -.
DR   ProteinModelPortal; P11362; -.
DR   SMR; P11362; -.
DR   BioGrid; 108551; 87.
DR   DIP; DIP-4019N; -.
DR   IntAct; P11362; 26.
DR   MINT; MINT-1499363; -.
DR   STRING; 9606.ENSP00000393312; -.
DR   BindingDB; P11362; -.
DR   ChEMBL; CHEMBL3650; -.
DR   DrugBank; DB08577; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB02058; SU4984.
DR   DrugBank; DB05014; XL999.
DR   GuidetoPHARMACOLOGY; 1808; -.
DR   iPTMnet; P11362; -.
DR   PhosphoSitePlus; P11362; -.
DR   SwissPalm; P11362; -.
DR   BioMuta; FGFR1; -.
DR   DMDM; 120046; -.
DR   EPD; P11362; -.
DR   MaxQB; P11362; -.
DR   PaxDb; P11362; -.
DR   PeptideAtlas; P11362; -.
DR   PRIDE; P11362; -.
DR   DNASU; 2260; -.
DR   Ensembl; ENST00000326324; ENSP00000327229; ENSG00000077782. [P11362-14]
DR   Ensembl; ENST00000335922; ENSP00000337247; ENSG00000077782. [P11362-20]
DR   Ensembl; ENST00000356207; ENSP00000348537; ENSG00000077782. [P11362-3]
DR   Ensembl; ENST00000397091; ENSP00000380280; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000397108; ENSP00000380297; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000397113; ENSP00000380302; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000425967; ENSP00000393312; ENSG00000077782. [P11362-21]
DR   Ensembl; ENST00000447712; ENSP00000400162; ENSG00000077782. [P11362-1]
DR   Ensembl; ENST00000484370; ENSP00000433163; ENSG00000077782. [P11362-15]
DR   Ensembl; ENST00000532791; ENSP00000432972; ENSG00000077782. [P11362-2]
DR   GeneID; 2260; -.
DR   KEGG; hsa:2260; -.
DR   UCSC; uc003xlp.4; human. [P11362-1]
DR   CTD; 2260; -.
DR   DisGeNET; 2260; -.
DR   GeneCards; FGFR1; -.
DR   GeneReviews; FGFR1; -.
DR   HGNC; HGNC:3688; FGFR1.
DR   HPA; CAB033614; -.
DR   HPA; HPA056402; -.
DR   HPA; HPA076274; -.
DR   MalaCards; FGFR1; -.
DR   MIM; 101600; phenotype.
DR   MIM; 123150; phenotype.
DR   MIM; 136350; gene.
DR   MIM; 147950; phenotype.
DR   MIM; 166250; phenotype.
DR   MIM; 190440; phenotype.
DR   MIM; 613001; phenotype.
DR   MIM; 615465; phenotype.
DR   neXtProt; NX_P11362; -.
DR   OpenTargets; ENSG00000077782; -.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 2117; Hartsfield-Bixler-Demyer syndrome.
DR   Orphanet; 2227; Hypodontia.
DR   Orphanet; 3366; Isolated trigonocephaly.
DR   Orphanet; 478; Kallmann syndrome.
DR   Orphanet; 168953; Myeloid neoplasm associated with FGFR1 rearrangement.
DR   Orphanet; 432; Normosmic congenital hypogonadotropic hypogonadism.
DR   Orphanet; 99798; Oligodontia.
DR   Orphanet; 2645; Osteoglophonic dwarfism.
DR   Orphanet; 93258; Pfeiffer syndrome type 1.
DR   Orphanet; 251612; Pilocytic astrocytoma.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   Orphanet; 3157; Septo-optic dysplasia.
DR   PharmGKB; PA28127; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P11362; -.
DR   KO; K04362; -.
DR   OMA; KVRDHMW; -.
DR   OrthoDB; EOG091G0CQZ; -.
DR   PhylomeDB; P11362; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1839120; Signaling by FGFR1 amplification mutants.
DR   Reactome; R-HSA-1839122; Signaling by activated point mutants of FGFR1.
DR   Reactome; R-HSA-190370; FGFR1b ligand binding and activation.
DR   Reactome; R-HSA-190373; FGFR1c ligand binding and activation.
DR   Reactome; R-HSA-190374; FGFR1c and Klotho ligand binding and activation.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-HSA-5654687; Downstream signaling of activated FGFR1.
DR   Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-HSA-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853336; Signaling by plasma membrane FGFR1 fusions.
DR   SignaLink; P11362; -.
DR   SIGNOR; P11362; -.
DR   ChiTaRS; FGFR1; human.
DR   EvolutionaryTrace; P11362; -.
DR   GeneWiki; Fibroblast_growth_factor_receptor_1; -.
DR   GenomeRNAi; 2260; -.
DR   PMAP-CutDB; P11362; -.
DR   PRO; PR:P11362; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000077782; -.
DR   CleanEx; HS_FGFR1; -.
DR   CleanEx; HS_FLG; -.
DR   ExpressionAtlas; P11362; baseline and differential.
DR   Genevisible; P11362; HS.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0090722; F:receptor-receptor interaction; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0060117; P:auditory receptor cell development; IEA:Ensembl.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0043009; P:chordate embryonic development; TAS:UniProtKB.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IEA:Ensembl.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; IEA:Ensembl.
DR   GO; GO:0030901; P:midbrain development; IEA:Ensembl.
DR   GO; GO:0042474; P:middle ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0090272; P:negative regulation of fibroblast growth factor production; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; TAS:UniProtKB.
DR   GO; GO:0001759; P:organ induction; IEA:Ensembl.
DR   GO; GO:0042473; P:outer ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0048339; P:paraxial mesoderm development; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000546; P:positive regulation of endothelial cell chemotaxis to fibroblast growth factor; IDA:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0090080; P:positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:1903465; P:positive regulation of mitotic cell cycle DNA replication; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:2000830; P:positive regulation of parathyroid hormone secretion; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0060665; P:regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling; IEA:Ensembl.
DR   GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:2001239; P:regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   GO; GO:0007037; P:vacuolar phosphate transport; IEA:Ensembl.
DR   GO; GO:0021847; P:ventricular zone neuroblast division; IEA:Ensembl.
DR   GO; GO:0070640; P:vitamin D3 metabolic process; IEA:Ensembl.
DR   CDD; cd05098; PTKc_FGFR1; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR028174; FGF_rcpt_1.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Complete proteome; Craniosynostosis;
KW   Cytoplasm; Cytoplasmic vesicle; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Dwarfism; Glycoprotein;
KW   Heparin-binding; Holoprosencephaly; Hypogonadotropic hypogonadism;
KW   Immunoglobulin domain; Kallmann syndrome; Kinase; Membrane;
KW   Mental retardation; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal;
KW   Transcription; Transcription regulation; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     21
FT   CHAIN        22    822       Fibroblast growth factor receptor 1.
FT                                /FTId=PRO_0000016780.
FT   TOPO_DOM     22    376       Extracellular. {ECO:0000255}.
FT   TRANSMEM    377    397       Helical. {ECO:0000255}.
FT   TOPO_DOM    398    822       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25    119       Ig-like C2-type 1.
FT   DOMAIN      158    246       Ig-like C2-type 2.
FT   DOMAIN      255    357       Ig-like C2-type 3.
FT   DOMAIN      478    767       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     484    490       ATP.
FT   NP_BIND     562    564       ATP.
FT   REGION      160    177       Heparin-binding.
FT   ACT_SITE    623    623       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028,
FT                                ECO:0000269|PubMed:19224897}.
FT   BINDING     514    514       ATP.
FT   BINDING     568    568       ATP.
FT   BINDING     627    627       ATP.
FT   BINDING     641    641       ATP.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                CNTRL-FGFR1 OR FGFR1-CNTRL fusion
FT                                proteins. {ECO:0000269|PubMed:10688839}.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                FGFR1OP-FGFR1 or FGFR1-FGFR1OP fusion
FT                                proteins. {ECO:0000269|PubMed:9949182}.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                FGFR1OP2-FGFR1.
FT                                {ECO:0000269|PubMed:15034873,
FT                                ECO:0000269|PubMed:16946300,
FT                                ECO:0000269|PubMed:17389761}.
FT   SITE        766    766       Mediates interaction with PLCG1 and SHB.
FT   MOD_RES     463    463       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     583    583       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     585    585       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     653    653       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:19665973,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     654    654       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:19665973,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     730    730       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     766    766       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19665973}.
FT   CARBOHYD     77     77       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    117    117       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    227    227       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    240    240       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    264    264       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    317    317       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     55    101       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    178    230
FT   DISULFID    277    341
FT   VAR_SEQ       1    160       Missing (in isoform 10, isoform 11,
FT                                isoform 12 and isoform 13).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_002957.
FT   VAR_SEQ       1     30       MWSWKCLLFWAVLVTATLCTARPSPTLPEQ -> MAAVTRD
FT                                FGEMLLHSGRVLPAE (in isoform 20).
FT                                {ECO:0000303|Ref.12}.
FT                                /FTId=VSP_041916.
FT   VAR_SEQ       1      1       M -> MEARVSLKRRIELTVEYPWRCGALSPTSNCRTGM
FT                                (in isoform 21).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041917.
FT   VAR_SEQ      31    119       Missing (in isoform 6, isoform 7, isoform
FT                                8, isoform 9, isoform 15, isoform 17 and
FT                                isoform 18).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1650441,
FT                                ECO:0000303|PubMed:1846977,
FT                                ECO:0000303|PubMed:2162671,
FT                                ECO:0000303|PubMed:2167437,
FT                                ECO:0000303|PubMed:7520751}.
FT                                /FTId=VSP_002958.
FT   VAR_SEQ      32     61       QPWGAPVEVESFLVHPGDLLQLRCRLRDDV -> CPDLQEA
FT                                KSCSASFHSITPLPFGLGTRLSD (in isoform 3).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009836.
FT   VAR_SEQ      62    822       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009837.
FT   VAR_SEQ     119    119       S -> SVPI (in isoform 19).
FT                                {ECO:0000303|PubMed:1652059,
FT                                ECO:0000303|PubMed:20139426}.
FT                                /FTId=VSP_038470.
FT   VAR_SEQ     120    150       DALPSSEDDDDDDDSSSEEKETDNTKPNRMP -> ACPDLQ
FT                                EAKWCSASFHSITPLPFGLGTRLSD (in isoform
FT                                16). {ECO:0000303|PubMed:1650441}.
FT                                /FTId=VSP_009838.
FT   VAR_SEQ     148    149       Missing (in isoform 14, isoform 15,
FT                                isoform 18, isoform 19 and isoform 21).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1650441,
FT                                ECO:0000303|PubMed:1652059,
FT                                ECO:0000303|PubMed:1662973,
FT                                ECO:0000303|PubMed:1722683,
FT                                ECO:0000303|PubMed:20139426,
FT                                ECO:0000303|PubMed:2162671,
FT                                ECO:0000303|PubMed:2167437,
FT                                ECO:0000303|PubMed:7520751,
FT                                ECO:0000303|Ref.12}.
FT                                /FTId=VSP_002959.
FT   VAR_SEQ     151    822       Missing (in isoform 16).
FT                                {ECO:0000303|PubMed:1650441}.
FT                                /FTId=VSP_009839.
FT   VAR_SEQ     313    391       TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHS
FT                                AWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMV ->
FT                                VIMAPVFVGQSTGKETTVSGAQVPVGRLSCPRMGSFLTLQA
FT                                HTLHLSRDLATSPRTSNRGHKVEVSWEQRAAGMGGAGL
FT                                (in isoform 17 and isoform 18).
FT                                {ECO:0000303|PubMed:2167437}.
FT                                /FTId=VSP_009840.
FT   VAR_SEQ     313    360       TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHS
FT                                AWLTVLE -> HSGINSSDAEVLTLFNVTEAQSGEYVCKVS
FT                                NYIGEANQSAWLTVTRP (in isoform 19).
FT                                {ECO:0000303|PubMed:1652059,
FT                                ECO:0000303|PubMed:20139426}.
FT                                /FTId=VSP_038471.
FT   VAR_SEQ     392    822       Missing (in isoform 17 and isoform 18).
FT                                {ECO:0000303|PubMed:2167437}.
FT                                /FTId=VSP_009841.
FT   VAR_SEQ     427    428       Missing (in isoform 20).
FT                                {ECO:0000303|Ref.12}.
FT                                /FTId=VSP_041918.
FT   VAR_SEQ     428    429       Missing (in isoform 4, isoform 5, isoform
FT                                8, isoform 9, isoform 12 and isoform 13).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_002960.
FT   VAR_SEQ     619    662       CIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTN
FT                                GRL -> VWNLKAPLVHTPRPGSQECPGDRGQCDEDSRLWP
FT                                RTGHSPHRLL (in isoform 2, isoform 5,
FT                                isoform 7, isoform 9, isoform 11 and
FT                                isoform 13).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009842.
FT   VAR_SEQ     663    822       Missing (in isoform 2, isoform 5, isoform
FT                                7, isoform 9, isoform 11 and isoform 13).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009843.
FT   VARIANT       4      4       W -> C (in HH2; unknown pathological
FT                                significance; dbSNP:rs760884357).
FT                                {ECO:0000269|PubMed:26277103}.
FT                                /FTId=VAR_074012.
FT   VARIANT      22     22       R -> S (in dbSNP:rs17175750).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019290.
FT   VARIANT      48     48       G -> S (in HH2; phenotype consistent with
FT                                normosmic idiopathic hypogonadotropic
FT                                hypogonadism; dbSNP:rs121909640).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030968.
FT   VARIANT      70     70       G -> R (in HH2; dbSNP:rs140254426).
FT                                {ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_072993.
FT   VARIANT      77     77       N -> K (in dbSNP:rs767195580).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030969.
FT   VARIANT      78     78       R -> C (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030970.
FT   VARIANT      96     96       S -> C (in HH2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26277103}.
FT                                /FTId=VAR_074013.
FT   VARIANT      97     97       G -> D (in HH2).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017885.
FT   VARIANT      99     99       Y -> C (in HH2; impairs the tertiary
FT                                folding resulting in incomplete
FT                                glycosylation and reduced cell surface
FT                                expression; dbSNP:rs727505373).
FT                                {ECO:0000269|PubMed:12627230,
FT                                ECO:0000269|PubMed:19820032}.
FT                                /FTId=VAR_017886.
FT   VARIANT     101    101       C -> F (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030971.
FT   VARIANT     102    102       V -> I (in HH2; dbSNP:rs55642501).
FT                                {ECO:0000269|PubMed:15605412,
FT                                ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030972.
FT   VARIANT     116    116       V -> I (in HH2; dbSNP:rs747842199).
FT                                {ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_072994.
FT   VARIANT     117    117       N -> S (in HH2; some patients also carry
FT                                GNRHR mutations; dbSNP:rs780765366).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069288.
FT   VARIANT     125    125       S -> L (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation;
FT                                dbSNP:rs121913473).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042201.
FT   VARIANT     129    129       D -> A (in HH2; dbSNP:rs765615419).
FT                                {ECO:0000269|PubMed:15605412}.
FT                                /FTId=VAR_030973.
FT   VARIANT     165    165       L -> S (in HRTFDS; dbSNP:rs397515481).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070851.
FT   VARIANT     167    167       A -> S (in HH2; with cleft palate, corpus
FT                                callosum agenesis, unilateral deafness
FT                                and fusion of fourth and fifth metacarpal
FT                                bones; dbSNP:rs121909630).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017887.
FT   VARIANT     174    174       V -> A (in HH2).
FT                                {ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_072995.
FT   VARIANT     178    178       C -> S (in HH2; with severe ear
FT                                anomalies).
FT                                {ECO:0000269|PubMed:16757108}.
FT                                /FTId=VAR_030974.
FT   VARIANT     191    191       L -> S (in HRTFDS; dbSNP:rs869025669).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070852.
FT   VARIANT     213    213       W -> G (in dbSNP:rs17851623).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_030975.
FT   VARIANT     224    224       D -> H (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030976.
FT   VARIANT     228    228       Y -> D (in HH2; some patients also carry
FT                                KISS1R mutations; impairs the tertiary
FT                                folding resulting in incomplete
FT                                glycosylation and reduced cell surface
FT                                expression).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069289.
FT   VARIANT     237    237       G -> D (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030977.
FT   VARIANT     237    237       G -> S (in HH2; with or without anosmia;
FT                                also found in a family member with
FT                                isolated anosmia; may impair proper
FT                                folding; dbSNP:rs121909635).
FT                                {ECO:0000269|PubMed:16606836}.
FT                                /FTId=VAR_030978.
FT   VARIANT     239    239       I -> T (in HH2; some patients also carry
FT                                PROKR2 and GNRH1 mutations; impairs the
FT                                tertiary folding resulting in incomplete
FT                                glycosylation and reduced cell surface
FT                                expression).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069290.
FT   VARIANT     245    245       L -> P (in HH2).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030979.
FT   VARIANT     250    250       R -> Q (in HH2; with or without anosmia;
FT                                results in Kallmann syndrome in the
FT                                presence of HS6ST1 mutation TRP-306;
FT                                reduces receptor affinity for fibroblast
FT                                growth factor; dbSNP:rs121909645).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:21700882,
FT                                ECO:0000269|PubMed:23643382,
FT                                ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_069291.
FT   VARIANT     250    250       R -> W (in HH2).
FT                                {ECO:0000269|PubMed:16882753,
FT                                ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030980.
FT   VARIANT     252    252       P -> R (in PS and JWS;
FT                                dbSNP:rs121909627).
FT                                {ECO:0000269|PubMed:10861678,
FT                                ECO:0000269|PubMed:7874169}.
FT                                /FTId=VAR_004111.
FT   VARIANT     252    252       P -> T (in a lung bronchoalveolar
FT                                carcinoma sample; somatic mutation;
FT                                dbSNP:rs121913472).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042202.
FT   VARIANT     254    254       R -> Q (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030981.
FT   VARIANT     270    270       G -> D (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030982.
FT   VARIANT     273    273       V -> M (in HH2).
FT                                {ECO:0000269|PubMed:15605412,
FT                                ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030983.
FT   VARIANT     274    274       E -> G (in HH2; also found in a family
FT                                member with isolated anosmia;
FT                                dbSNP:rs727505369).
FT                                /FTId=VAR_030984.
FT   VARIANT     277    277       C -> Y (in HH2).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017888.
FT   VARIANT     283    283       P -> R (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030985.
FT   VARIANT     300    300       I -> T (in TRIGNO1; dbSNP:rs121909633).
FT                                {ECO:0000269|PubMed:11173846}.
FT                                /FTId=VAR_030986.
FT   VARIANT     330    330       N -> I (in OGD; dbSNP:rs121909632).
FT                                {ECO:0000269|PubMed:15625620,
FT                                ECO:0000269|PubMed:16470795}.
FT                                /FTId=VAR_030987.
FT   VARIANT     332    332       S -> C (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030988.
FT   VARIANT     339    339       Y -> C (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030989.
FT   VARIANT     342    342       L -> S (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a splice site mutation in NSMF;
FT                                dbSNP:rs121909638).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069954.
FT   VARIANT     343    343       A -> V (in HH2).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030990.
FT   VARIANT     346    346       S -> C (in HH2; also found in a family
FT                                member with isolated anosmia).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030991.
FT   VARIANT     348    348       G -> R (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a mutation in IL17RD).
FT                                {ECO:0000269|PubMed:23643382,
FT                                ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_069955.
FT   VARIANT     366    366       P -> L (in HH2; with or without anosmia;
FT                                dbSNP:rs121909641).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030992.
FT   VARIANT     374    374       Y -> C (in OGD; elevated basal activity
FT                                and increased FGF2-mediated activity;
FT                                dbSNP:rs121909631).
FT                                {ECO:0000269|PubMed:15625620}.
FT                                /FTId=VAR_030993.
FT   VARIANT     381    381       C -> R (in OGD; dbSNP:rs121909634).
FT                                {ECO:0000269|PubMed:15625620,
FT                                ECO:0000269|PubMed:16470795}.
FT                                /FTId=VAR_030994.
FT   VARIANT     470    470       R -> L (in HH2; some patients also carry
FT                                GNRHR mutations; dbSNP:rs121909637).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069292.
FT   VARIANT     483    483       P -> T (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a rare variant in SPRY4;
FT                                dbSNP:rs397515444).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069956.
FT   VARIANT     490    490       G -> R (in HRTFDS; dbSNP:rs869025670).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070853.
FT   VARIANT     520    520       A -> T (in HH2; dbSNP:rs749758370).
FT                                {ECO:0000269|PubMed:15605412}.
FT                                /FTId=VAR_030995.
FT   VARIANT     538    538       I -> V (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030996.
FT   VARIANT     546    546       N -> K (in ECCL; somatic mutation;
FT                                activating mutation; strongly increased
FT                                speed of the first autophosphorylation
FT                                and loss of the normal sequential order
FT                                of autophosphorylation).
FT                                {ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:26942290}.
FT                                /FTId=VAR_075853.
FT   VARIANT     561    561       V -> M. {ECO:0000269|PubMed:26942290}.
FT                                /FTId=VAR_075854.
FT   VARIANT     607    607       V -> M (in HH2; with bimanual synkinesis;
FT                                dbSNP:rs121909629).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017889.
FT   VARIANT     618    618       K -> N (in HH2; some patients also carry
FT                                GNRHR mutations; impairs tyrosine kinase
FT                                activity). {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069293.
FT   VARIANT     621    621       H -> R (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030997.
FT   VARIANT     622    622       R -> G (in HH2; with severe ear
FT                                anomalies).
FT                                {ECO:0000269|PubMed:16757108}.
FT                                /FTId=VAR_030998.
FT   VARIANT     622    622       R -> Q (in HH2).
FT                                {ECO:0000269|PubMed:16757108}.
FT                                /FTId=VAR_030999.
FT   VARIANT     623    623       D -> Y (in HRTFDS; dbSNP:rs398122946).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070854.
FT   VARIANT     627    627       R -> T (in HRTFDS; dbSNP:rs869025671).
FT                                {ECO:0000269|PubMed:24888332}.
FT                                /FTId=VAR_071460.
FT   VARIANT     628    628       N -> K (in HRTFDS; dbSNP:rs869025672).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070855.
FT   VARIANT     656    656       K -> E (in ECCL; somatic mutation).
FT                                {ECO:0000269|PubMed:26942290}.
FT                                /FTId=VAR_075855.
FT   VARIANT     664    664       V -> L (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042203.
FT   VARIANT     666    666       W -> R (in HH2; with cleft palate).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017890.
FT   VARIANT     670    670       E -> K (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a rare variant in FLRT3;
FT                                dbSNP:rs397515446).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069957.
FT   VARIANT     671    671       A -> P (in HH2).
FT                                {ECO:0000269|PubMed:19820032}.
FT                                /FTId=VAR_069294.
FT   VARIANT     685    685       S -> F (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_031000.
FT   VARIANT     687    687       G -> R (in HH2; dbSNP:rs727505376).
FT                                {ECO:0000269|PubMed:15845591,
FT                                ECO:0000269|PubMed:22927827}.
FT                                /FTId=VAR_031001.
FT   VARIANT     692    692       E -> G (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a rare variant in DUSP6;
FT                                dbSNP:rs397515445).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069958.
FT   VARIANT     693    693       I -> F (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_031002.
FT   VARIANT     703    703       G -> R (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_031003.
FT   VARIANT     703    703       G -> S (in HH2; dbSNP:rs768957161).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_031004.
FT   VARIANT     719    719       M -> R (in HH2).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017891.
FT   VARIANT     719    719       M -> V (in HH2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26277103}.
FT                                /FTId=VAR_074014.
FT   VARIANT     722    722       P -> H (in HH2; associated with K-724;
FT                                also found in a family member with
FT                                isolated anosmia; reduced tyrosine kinase
FT                                activity; dbSNP:rs267606805).
FT                                {ECO:0000269|PubMed:16606836,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_031005.
FT   VARIANT     722    722       P -> S (in HH2; dbSNP:rs121909642).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_031006.
FT   VARIANT     724    724       N -> K (in HH2; associated with H-722;
FT                                also found in a family member with
FT                                isolated anosmia; reduced tyrosine kinase
FT                                activity; dbSNP:rs267606806).
FT                                {ECO:0000269|PubMed:16606836,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_031007.
FT   VARIANT     725    725       C -> Y (in HRTFDS; dbSNP:rs398122945).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070856.
FT   VARIANT     745    745       P -> S (in HH2).
FT                                {ECO:0000269|PubMed:15001591,
FT                                ECO:0000269|PubMed:15845591}.
FT                                /FTId=VAR_031008.
FT   VARIANT     768    768       D -> Y (in HH2; the patient also carries
FT                                a rare variant in FGF8;
FT                                dbSNP:rs121909644).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069959.
FT   VARIANT     769    769       L -> V (in dbSNP:rs2956723).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_031009.
FT   VARIANT     772    772       P -> S (in HH2; with cleft palate,
FT                                unilateral absence of nasal cartilage,
FT                                iris coloboma; dbSNP:rs56234888).
FT                                {ECO:0000269|PubMed:12627230,
FT                                ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_017892.
FT   VARIANT     795    795       V -> I (in HH2; also found in a family
FT                                member with isolated anosmia;
FT                                dbSNP:rs781328162).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_031010.
FT   VARIANT     818    818       G -> R (in dbSNP:rs17182456).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019291.
FT   VARIANT     822    822       R -> C (in dbSNP:rs17182463).
FT                                {ECO:0000269|PubMed:17154279,
FT                                ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019292.
FT   MUTAGEN     514    514       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15117958}.
FT   MUTAGEN     577    577       R->E: Strongly reduced
FT                                autophosphorylation in response to FGF
FT                                signaling. No effect on in vitro kinase
FT                                activity. {ECO:0000269|PubMed:20133753}.
FT   MUTAGEN     609    609       R->V: Abolishes interaction with PLCG1.
FT   MUTAGEN     623    623       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19224897}.
FT   MUTAGEN     653    653       Y->F: No effect on kinase activity. Loss
FT                                of autophosphorylation and kinase
FT                                activity; when associated with F-654.
FT                                {ECO:0000269|PubMed:8622701}.
FT   MUTAGEN     654    654       Y->F: Reduced kinase activity. Loss of
FT                                autophosphorylation and kinase activity;
FT                                when associated with F-653.
FT                                {ECO:0000269|PubMed:8622701}.
FT   MUTAGEN     755    755       D->V: Abolishes interaction with PLCG1.
FT   MUTAGEN     766    766       Y->F: Abolishes interaction with PLCG1
FT                                and SHB. Decreases phosphorylation of
FT                                FRS2, activation of RAS and MAP kinase
FT                                signaling and stimulation of cell
FT                                proliferation.
FT                                {ECO:0000269|PubMed:12181353,
FT                                ECO:0000269|PubMed:1379697,
FT                                ECO:0000269|PubMed:1379698,
FT                                ECO:0000269|PubMed:7516330}.
FT   CONFLICT     24     24       S -> C (in Ref. 8; AAA35958/AAA35959).
FT                                {ECO:0000305}.
FT   CONFLICT    192    192       K -> E (in Ref. 3; AAA35837).
FT                                {ECO:0000305}.
FT   CONFLICT    194    194       G -> S (in Ref. 5; AAA35835).
FT                                {ECO:0000305}.
FT   CONFLICT    196    196       E -> G (in Ref. 16; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    223    223       S -> F (in Ref. 12; BAD96438).
FT                                {ECO:0000305}.
FT   CONFLICT    308    308       V -> A (in Ref. 8; AAA35958/AAA35959).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       E -> Q (in Ref. 18; CAA68679).
FT                                {ECO:0000305}.
FT   CONFLICT    469    469       P -> L (in Ref. 1; AAA75007).
FT                                {ECO:0000305}.
FT   CONFLICT    482    482       K -> R (in Ref. 12; BAD96438).
FT                                {ECO:0000305}.
FT   CONFLICT    576    576       R -> W (in Ref. 12; BAD96438).
FT                                {ECO:0000305}.
FT   CONFLICT    817    817       G -> R (in Ref. 4; CAA36101).
FT                                {ECO:0000305}.
FT   STRAND       40     42       {ECO:0000244|PDB:2CR3}.
FT   STRAND       51     54       {ECO:0000244|PDB:2CR3}.
FT   STRAND       63     72       {ECO:0000244|PDB:2CR3}.
FT   STRAND       77     81       {ECO:0000244|PDB:2CR3}.
FT   STRAND       83     88       {ECO:0000244|PDB:2CR3}.
FT   TURN         93     95       {ECO:0000244|PDB:2CR3}.
FT   STRAND       97    105       {ECO:0000244|PDB:2CR3}.
FT   STRAND      108    116       {ECO:0000244|PDB:2CR3}.
FT   STRAND      151    156       {ECO:0000244|PDB:1CVS}.
FT   HELIX       158    161       {ECO:0000244|PDB:1CVS}.
FT   STRAND      165    169       {ECO:0000244|PDB:1CVS}.
FT   STRAND      174    177       {ECO:0000244|PDB:1CVS}.
FT   STRAND      180    184       {ECO:0000244|PDB:1CVS}.
FT   STRAND      187    192       {ECO:0000244|PDB:1CVS}.
FT   HELIX       199    201       {ECO:0000244|PDB:1CVS}.
FT   STRAND      207    209       {ECO:0000244|PDB:1CVS}.
FT   TURN        210    213       {ECO:0000244|PDB:1CVS}.
FT   STRAND      214    219       {ECO:0000244|PDB:1CVS}.
FT   HELIX       222    224       {ECO:0000244|PDB:1CVS}.
FT   STRAND      226    234       {ECO:0000244|PDB:1CVS}.
FT   STRAND      237    248       {ECO:0000244|PDB:1CVS}.
FT   STRAND      265    267       {ECO:0000244|PDB:1CVS}.
FT   STRAND      273    276       {ECO:0000244|PDB:1CVS}.
FT   STRAND      286    293       {ECO:0000244|PDB:1CVS}.
FT   STRAND      295    297       {ECO:0000244|PDB:1CVS}.
FT   STRAND      306    313       {ECO:0000244|PDB:1CVS}.
FT   HELIX       320    323       {ECO:0000244|PDB:1CVS}.
FT   STRAND      325    328       {ECO:0000244|PDB:1CVS}.
FT   HELIX       333    335       {ECO:0000244|PDB:1CVS}.
FT   STRAND      337    344       {ECO:0000244|PDB:1CVS}.
FT   STRAND      349    358       {ECO:0000244|PDB:1CVS}.
FT   HELIX       460    462       {ECO:0000244|PDB:4UWC}.
FT   TURN        469    471       {ECO:0000244|PDB:5EW8}.
FT   HELIX       475    477       {ECO:0000244|PDB:5EW8}.
FT   STRAND      478    486       {ECO:0000244|PDB:5EW8}.
FT   STRAND      488    499       {ECO:0000244|PDB:5EW8}.
FT   STRAND      501    503       {ECO:0000244|PDB:5EW8}.
FT   STRAND      508    516       {ECO:0000244|PDB:5EW8}.
FT   HELIX       522    538       {ECO:0000244|PDB:5EW8}.
FT   STRAND      547    551       {ECO:0000244|PDB:5EW8}.
FT   STRAND      553    555       {ECO:0000244|PDB:5EW8}.
FT   STRAND      558    562       {ECO:0000244|PDB:5EW8}.
FT   HELIX       569    574       {ECO:0000244|PDB:5EW8}.
FT   STRAND      579    583       {ECO:0000244|PDB:4RWI}.
FT   STRAND      584    586       {ECO:0000244|PDB:5A4C}.
FT   HELIX       591    593       {ECO:0000244|PDB:3KXX}.
FT   HELIX       597    616       {ECO:0000244|PDB:5EW8}.
FT   HELIX       626    628       {ECO:0000244|PDB:5EW8}.
FT   STRAND      629    631       {ECO:0000244|PDB:5EW8}.
FT   STRAND      637    639       {ECO:0000244|PDB:5EW8}.
FT   STRAND      641    643       {ECO:0000244|PDB:3JS2}.
FT   HELIX       648    650       {ECO:0000244|PDB:5EW8}.
FT   STRAND      653    655       {ECO:0000244|PDB:4UWY}.
FT   STRAND      658    660       {ECO:0000244|PDB:5AM7}.
FT   HELIX       663    666       {ECO:0000244|PDB:5EW8}.
FT   HELIX       669    674       {ECO:0000244|PDB:5EW8}.
FT   STRAND      676    678       {ECO:0000244|PDB:3GQI}.
FT   HELIX       679    694       {ECO:0000244|PDB:5EW8}.
FT   HELIX       706    714       {ECO:0000244|PDB:5EW8}.
FT   STRAND      722    724       {ECO:0000244|PDB:4RWL}.
FT   HELIX       727    736       {ECO:0000244|PDB:5EW8}.
FT   HELIX       741    743       {ECO:0000244|PDB:5EW8}.
FT   HELIX       747    760       {ECO:0000244|PDB:5EW8}.
SQ   SEQUENCE   822 AA;  91868 MW;  93A01B5D78C3E72C CRC64;
     MWSWKCLLFW AVLVTATLCT ARPSPTLPEQ AQPWGAPVEV ESFLVHPGDL LQLRCRLRDD
     VQSINWLRDG VQLAESNRTR ITGEEVEVQD SVPADSGLYA CVTSSPSGSD TTYFSVNVSD
     ALPSSEDDDD DDDSSSEEKE TDNTKPNRMP VAPYWTSPEK MEKKLHAVPA AKTVKFKCPS
     SGTPNPTLRW LKNGKEFKPD HRIGGYKVRY ATWSIIMDSV VPSDKGNYTC IVENEYGSIN
     HTYQLDVVER SPHRPILQAG LPANKTVALG SNVEFMCKVY SDPQPHIQWL KHIEVNGSKI
     GPDNLPYVQI LKTAGVNTTD KEMEVLHLRN VSFEDAGEYT CLAGNSIGLS HHSAWLTVLE
     ALEERPAVMT SPLYLEIIIY CTGAFLISCM VGSVIVYKMK SGTKKSDFHS QMAVHKLAKS
     IPLRRQVTVS ADSSASMNSG VLLVRPSRLS SSGTPMLAGV SEYELPEDPR WELPRDRLVL
     GKPLGEGCFG QVVLAEAIGL DKDKPNRVTK VAVKMLKSDA TEKDLSDLIS EMEMMKMIGK
     HKNIINLLGA CTQDGPLYVI VEYASKGNLR EYLQARRPPG LEYCYNPSHN PEEQLSSKDL
     VSCAYQVARG MEYLASKKCI HRDLAARNVL VTEDNVMKIA DFGLARDIHH IDYYKKTTNG
     RLPVKWMAPE ALFDRIYTHQ SDVWSFGVLL WEIFTLGGSP YPGVPVEELF KLLKEGHRMD
     KPSNCTNELY MMMRDCWHAV PSQRPTFKQL VEDLDRIVAL TSNQEYLDLS MPLDQYSPSF
     PDTRSSTCSS GEDSVFSHEP LPEEPCLPRH PAQLANGGLK RR
//
